Role of P2X7 and P2Y2 receptors on α-secretase-dependent APP processing: Control of amyloid plaques formation “in vivo” by P2X7 receptor
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Amyloid precursor protein (APP) is expressed in a large variety of neural and non-neural cells. The balance between non-pathogenic and pathologic forms of APP processing, mediated by α-secretase and β-secretase respectively, remains a crucial step to understand β-amyloid, Aβ42 peptide, formation and aggregation that are at the origin of the senile plaques in the brain, a characteristic hallmark of Alzheimer's disease (AD). In Neuro-2a, a neuroblastoma cell line that constitutively expresses APP, activation of the P2X7 receptor leads to reduction of α-secretase activity, the opposite effect being obtained by P2Y2 receptor activation. The in vivo approach was made possible by the use of J20 mice, a transgenic mouse model of familial Alzheimer's disease (FAD) expressing human APP mutant protein. This animal exhibits prominent amyloid plaques by six months of age. In vivo inhibition of the P2X7 receptor induced a significant decrease in the number and size of hippocampal amyloid plaques. This reduction is mediated by an increase in the proteolytic processing of APP through α-secretase activity, which correlates with an increase in the phosphorylated form of GSK-3, a less active form of this enzyme. The in vivo findings corroborate the therapeutic potential of P2X7 antagonists in the treatment of FAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
The genetics of Alzheimer disease
Tanzi, R. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006296 · Cited by 727
Morris, J. C., Storandt, M., McKeel, D. W., Rubin, E. H., Price, J. L., Grant, E. A., & Berg, L. (1996) · Neurology · doi:10.1212/wnl.46.3.707 · Cited by 603 · cited 1×
“…locate /csb j Mini Review Role of P2X7 and P2Y2 receptors on α-secretase-dependent APP processing: Control of amyloid plaques formation “in vivo” by P2X7 receptor M. Teresa Miras-Portugal ⁎, Juan I. Diaz-Hernandez, Rosa Gomez-Villafuertes, Miguel Diaz-Hernandez, Antonio R. Artalejo, Javier Gualix”
BackgroundParvathenani, L. K., Tertyshnikova, S., Greco, C. R., Roberts, S. B., Robertson, B., & Posmantur, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209478200 · Cited by 488 · cited 2×
“This fact is relevant because to date, most of the effects of P2X7, and also P2Y2, receptors have been explained by microglia activation around the senile plaques due to the amyloid Aβ-42 peptide or the release of extracellular nucleotides and cytokines, thus helping in the extracellular clearance of the amyloid depos…”
BackgroundP2X7 receptor: an emerging target in central nervous system diseases
Sperlágh, B., & Illes, P. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.08.002 · Cited by 390 · cited 1×
“…locate /csb j Mini Review Role of P2X7 and P2Y2 receptors on α-secretase-dependent APP processing: Control of amyloid plaques formation “in vivo” by P2X7 receptor M. Teresa Miras-Portugal ⁎, Juan I. Diaz-Hernandez, Rosa Gomez-Villafuertes, Miguel Diaz-Hernandez, Antonio R. Artalejo, Javier Gualix”
BackgroundActivation of Microglia by Amyloid β Requires P2X7 Receptor Expression
Sanz, J. M., Chiozzi, P., Ferrari, D., Colaianna, M., Idzko, M., Falzoni, S., Fellin, R., Trabace, L., & Di Virgilio, F. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803612 · Cited by 293 · cited 2×
“This fact is relevant because to date, most of the effects of P2X7, and also P2Y2, receptors have been explained by microglia activation around the senile plaques due to the amyloid Aβ-42 peptide or the release of extracellular nucleotides and cytokines, thus helping in the extracellular clearance of the amyloid depos…”
BackgroundThe role of G protein-coupled receptors in the pathology of Alzheimer's disease
Thathiah, A., & De Strooper, B. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2977 · Cited by 288 · cited 1×
“The possibility of enhancing the non-amyloidogenic APP processing by different G protein-coupled neurotransmitter receptors (GPCRs) has been postulated, and modulation of the α-, β- and γ-secretases action on APP by diverse signaling cascades has been proved [17].”
BackgroundA role for tau at the synapse in Alzheimer’s disease pathogenesis
Pooler, A. M., Noble, W., & Hanger, D. P. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.09.018 · Cited by 203 · cited 1×
“Although most of the effects reported for tau are at the intracellular level [8], it has been recently reported that extracellular tau and its peptide fragments behave as non-desensitizing agonists onmuscarinicM1 andM3 receptors, with a sustained cytosolic Ca increase in neural cells [9,10].”
BackgroundAplin, A. E., Gibb, G. M., Jacobsen, J. S., Gallo, J., & Anderton, B. H. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67020699.x · Cited by 201 · cited 1×
“It has been reported that an increase in GSK-3 activity [18] correlates with the phosphorylation of APP intracellular domain, making it a more suitable substrate for γ-secretase proteolysis, which enhances Aβ-42 production [19].”
BackgroundSabo, S. L., Ikin, A. F., Buxbaum, J. D., & Greengard, P. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-13-05407.2003 · Cited by 187 · cited 1×
“P2X7 receptor immunolabelling shows a distribution similar to that observed for APP, being present not only in the neuronal cell body, but also in the axon-like extension [37,38] (Fig.”
BackgroundToward the Treatment and Prevention of Alzheimer's Disease: Rational Strategies and Recent Progress
Gandy, S., & DeKosky, S. T. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-092611-084441 · Cited by 110 · cited 1×
“These studies allowed the identification of a large number of genes, some related with innate immunity, cellular signaling or Aβ clearance, which has contributed to open the field to new views and interpretations [15,16].”
BackgroundAxonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells
Brunholz, S., Sisodia, S., Lorenzo, A., Deyts, C., Kins, S., & Morfini, G. (2012) · Experimental Brain Research · doi:10.1007/s00221-011-2870-1 · Cited by 92 · cited 1×
“These results contrast with those obtained by other authors, but it is relevant to emphasize that APP processing depends on the abundance of this protein at the specific cellular model and in addition, when it is overexpressed, the equilibrium between the different proteolytic pathways could be unbalanced, making it m…”
Result
Cited by
The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
Savio, L. E. B., de Andrade Mello, P., da Silva, C. G., & Coutinho-Silva, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00052 · Cited by 437
“Accordingly, two independent studies demonstrated that BzATP-induced P2X7 receptor activation leads to decreased α-secretase activity, which was prevented by P2X7 receptor antagonists and P2X7 receptor siRNA (León-Otegui et al., 2011; Miras-Portugal et al., 2015).”
BackgroundPurinergic Signalling: Therapeutic Developments
Burnstock, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00661 · Cited by 398
Burnstock, G., & Knight, G. E. (2018) · Purinergic Signalling · doi:10.1007/s11302-017-9593-0 · Cited by 248
The P2X7 Receptor: Central Hub of Brain Diseases
Andrejew, R., Oliveira-Giacomelli, Á., Ribeiro, D. E., Glaser, T., Arnaud-Sampaio, V. F., Lameu, C., & Ulrich, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00124 · Cited by 162
“…lines (HEK293T and neuroblastoma N2a), inhibition of either constitutive expression or overexpression of the P2X7 receptor increased α-secretase activity through inhibition of glycogen synthase kinase 3 (GSK-3) (León-Otegui et al., 2011; Diaz-Hernandez et al., 2012; Miras-Portugal et al., 2015).”
BackgroundResultInfluentialThe P2X7 Receptor Primes IL-1β and the NLRP3 Inflammasome in Astrocytes Exposed to Mechanical Strain
Albalawi, F., Lu, W., Beckel, J. M., Lim, J. C., McCaughey, S. A., & Mitchell, C. H. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00227 · Cited by 155
Metadata
- Authors
- Miras-Portugal, M. T., Diaz-Hernandez, J. I., Gomez-Villafuertes, R., Diaz-Hernandez, M., Artalejo, A. R., & Gualix, J.
- Venue
- Computational and Structural Biotechnology Journal
- Published
- 2015
- Volume
- 13
- Pages
- 176-181
- ISSN
- 2001-0370 (ISSN-L)
- OpenAlex
- W2034579767
- Cited by
- 34
- References
- 12
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.